Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

NCT03697629 is registered in ClinicalTrials.gov with Canadian Myeloma Research Group as lead sponsor.

NCT NCT03697629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Canadian Myeloma Research Group
Phase
Phase 2
Overall status
Completed
Start date
December 3, 2018
Completion date
December 20, 2021
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse